ASCO 2026 plenary data establishes daraxonrasib as the new second-line standard of care for advanced pancreatic tumors.

Researchers at the University of Cologne's Center for Molecular Medicine Cologne (CMMC) have discovered a previously unknown ...

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to ...

Mutations of KRAS have long been targets of interest for the development of new cancer therapies, but structural changes caused by these mutations have made it particularly difficult to target and ...

Verastem doses first patient in TARGET-D 201, a registration-directed Phase 2 trial of VS-7375 in KRAS G12D-mutated advanced ...

A new pancreatic cancer treatment may finally move the needle on what's proved to be an unforgiving disease. Fred Hutch ...

Anocca AB (‘Anocca’ or the ‘Company’), a clinical-stage biotechnology company developing advanced T-cell immunotherapies, today announced the successful dosing of the first patients across multiple ...

KRAS‑mutant pancreatic cancer relies on caspase‑8 to evade necroptosis, according to a new study in preclinical models.

A new research paper was published in Volume 17 of Oncotarget on June 3, 2026, titled "The anticancer effects of PCAIs in ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...

Share on Pinterest New research shows certain KRAS mutations in pancreatic cancer may improve survival rates compared to other mutations. William Taufic/Getty Images In 2020, more than 495,000 adults ...